МУАЛЛИФЛАР ДИҚҚАТИГА

“Наманган муҳандислик-технология институти

Илмий-техника журнали” журналнинг навбатдаги
сонига мақолалар қабулини журналнинг расмий сайти
www.niet.uz орқали мақолалар қабулини бошлади.
НамМТИ илмий-техника журнали 2023-йил 1-сонидан
бошлаб қуйидаги ҳалқаро ва республика илмий
маълумотлар базаларида индексланади
- Google schoolar
- Slib.uz
Ҳамда ҳар бир мақола учун DOI рақам берилдади.
Илмий мақолаларга қўйилган талаблар

➢ Мақолалар фақат инглиз тилида чоп этилади, лекин

таҳририятга 2 нусхада (инглиз ва ўзбек) тақдим этилиши
шарт;
➢ Мақола Times New Roman шрифтида, 12pt катталикда,
1.0 интервалда, юқори, ўнг, чап ҳамда паст томонидан 2,5
см жой қолдириб MS-WORD 2003-2010 дастурида
расмийлаштирилиши лозим;
➢ Мақола тегишли фан йўналиши бўйича фан докторининг
расмий тақризи ҳамда чоп этиш мумкинлиги ҳақида
экспертиза хулосаси билан бирга https://antiplag.uz/
плагиат натижасини (70% дан кам бўлмаслиги керак)
юқоридаги сайт орқали электрон тарзда юборилади. Шу
билан бирга, таҳририят мақолани қўшимча равишда
тақризга тақдим этади ва 10 иш кун муддатида ушбу
тақриз натижалари асосида мақолани чоп этиш масаласи
бўйича тегишли қарорга келади;
➢ Мақоладаги маълумотлар, фактлар ва статистик
маълумотларнинг тўғрилигига муаллифлар масъулдир;
➢ Журналнинг бир сонида битта муаллифнинг фақатгина
битта мақоласи чоп этилади;
➢ Мақолада албатта жадвал, чизма, гистограмма ёки шу
 каби манбалар аниқ кўрсатилиши, расм кўринишида
эмас, тегишли дастурлар ёрдамида шакллантирилиши,
қисқартма сўзларга изоҳ берилиши лозим.
➢ Мақола сарлавҳаси катта ҳарфларда, қорайтирилган
ҳолда, ундан кейин эса муаллифнинг Ф.И.О (тўлиқ) ва
аффилацияси, электрон манизили ва телефон рақами ҳам
албатта келтириб ўтилиши керак;
➢ Мақоланинг аннотацияси(abstract) яъни мақоланинг
қисқача мазмунида мақсади (objective), усуллари
(methods), натижалари(results) ва хулоса (conclusion)
қисмлари қисқача ёритилиб ўтилиши шарт. Чунки
мақола аннотациясини ўқиб чиқиб, олим мақолани
тўлиқ ўқишга қарор қилиши учун мақоланинг асосий
тушунчаларини етарлича тушиниши керак.
Аннотациядан сўнг мавзуга тегишли терминлар, калит
сўзлар(keywords) ҳам келтирилиши керак;
➢ Мақоланинг асосий қисмида Кириш (Introduction),
усуллари (methods) , натижалар (results), муҳокамалар
(discussion), ва хулосалар (conclusion) бўлимлари аниқ
маълумотлар асосида ёритиб берилиши керак.
➢ Таҳририятга тақдим этилаётган илмий мақолалар 5-7
саҳифадан иборат бўлиши агарда ундан ортиқ бўлса ҳар
бири саҳифаси учун 20,0 минг сўмдан қўшимча тўлов
амалга оширилади;
➢ Адабиётлар рўйхати камида 20 тадан кам бўлмаслиги
керак.
Адабиётлар қуйидаги кетма-кетликда
расмийлаштирилади: Муаллиф(лар) исми(лар), мақола
номи, китоб номи, нашр этилган йили, ношир, нашриёт
манзили ва саҳифаси.
➢ Қуйида мақола расмийлаштириш бўйича намуна
келтирилган шу намуна асосида шакллантириш тавсия
этилади. Намуна шунчаки шакл ва тузилишини
кўрсатиш учун таҳлил этиш учун эмас.
 NAMUNA(SAMPLE)

MAQOLA NOMI, MAQOLA NOMI, MAQOLA NOMI

(Times New Roman 14 shrift)

Kodirov Olimjon
(Times New Roman 12 shrift)
Assistant of Namangan institute of engineering and technology
Tel.: (99890) 641-1996, e-mail: olimjonqodirov18@gmail.com
(Times New Roman 8 shrift)

Abstract.
Objective. Patients with low-risk MDS remain dependent on regular transfusions, acquiring a secondary,
post-transfusion excess of iron, which accordingly is an indication for the appointment of chelation therapy (CT).
All over the world this problem continues to be studied, confirmation that this article cites about 40 sources of
literature review.
Methods. Three online medical databases were searched to identify studies reporting the data on the
complex methods of treatment for the correction of iron deficiency condition in patients with low risk
myelodysplastic syndrome. The primary outcome was to learn the worldwide tendency on this matter and to
compare the results of different authors.
Results. Several primary and secondary studies have been published that demonstrate improved survival of
low-risk MDS patients who received chemotherapy. Overall, we identified 842 items as a result of search. Then
we found 156 studies as similar among the databases that were deleted afterwards. Then, remaining 686 records
were screened excluding 512 findings owing to different reasons. Further, the titles of 174 studies were read, 51
articles found as potentially eligible, which obtained in full text. All full text articles were learnt by the authors of
the review. Finally, we included 26 studies to our review.
Conclusion. Chelator therapy is a component of the treatment for low-risk MDS patients with post-
transfusion overload with iron. Its appointment as part of a complex-pathogenetical therapy should not be formal.
The description of iron chelators can reduce transfusion dependence and increase survival in patients with MDS.
Keywords: myelodysplastic syndrome (MDS), acute leukemia, low-risk MDS patients, anemia, ferritin,
erythropoiesis-stimulating drugs, chelator therapy, exjade.
(Times New Roman 10 shrift)

Introduction. Myelodysplastic syndrome (MDS) is a group of heterogeneous clonal

diseases characterized by the presence of cytopenia in peripheral blood (PB), bone marrow
(BM) dysplasia and the risk of transformation into acute leukemia (AL). MDS is one of the most
severe issues in hematology today. MDS is more specific pathology for the older age group.
80% of cases with MDS occur in people over 60. Childhood MDS is extremely rare. It is known
that the choice of therapeutic tactics is largely determined by the patient's age, somatic
condition, risk level by IPSS and WPSS scale, as well as the availability of a suitable
donor…………………………………….....................................................................................
Methods. The literature review was conducted following the guidelines set by the
PreferredReporting Items for Systematic Reviews andMeta-Analysis (PRISMA) (Moher et al,
2009)................................................................................................................................................
 Results. Overall, 842 items found as a result of search through databases mentioned above.
Next, we identified 156 identical studies that were deleted afterwards. Then, remaining 686
records were screened excluding 512 findings owing to different reasons. Further, the titles of
174 studies were read, 51 articles found as potentially eligible, which obtained in full text. All
full text articles were learnt by the authors of the review. Finally, we included 26 studies to our
review. Owing to the different style, methods and outcomes of the studies (heterogeneity), we
did not perform metaanalysis........................................................................................................

Discussions. The review of the recent literature on the topic of complex treatment of iron
deficiency condition in patients with low risk myelodysplastic syndrome showed that there are
some shortcomings in studies evaluating the effectiveness of chelators. Moreover, this includes
the lack of randomization and the possible selection of patients with a more favorable prognosis
in the CT group, yet, the available data allow us to expect improved survival and reduced
transfusion dependence when prescribing iron chelators.

Conclusion. Chelator therapy is a component of the algorithm of treatmentfor low-risk

MDS patients with post-transfusion overload with iron. Its appointment as part of a
complexpathogenetical therapy should not be formal due to only the identification of criteria for
excess iron in the body. The description of iron chelators can reduce transfusion dependence and
increase survival in patients with MDS. The conditions for a
complexpathogeneticallysubstantiated manifestation of the clinical effectiveness of chelator
therapy are careful selection of candidates, timely dose adjustment and long-term use of
chelators. In Uzbekistan, chelator therapy with the use of exjade in patients with thalassemia is
successfully used, only the complex pathogenetically substantiated prescription of therapeutic
drugs is provided at the expense of statefunds.................................................................................

REFERENCES
1. Malcovati L, Porta MG, Pascutto C “Prognostic factors and life expectancy in
myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision
making”. J ClinOncol; 2005, 23 (30): pp. 7594-7603.
2. Suleymanova DN. “The risk of iron overload and chelator therapy in patients with
thalassemia”.Methodological manual. 2017, Tashkent. p. 39

(Times New Roman 12 shrift)

 SAYT ORQALI MAQOLA TAQDIM ETISH KETMA-KETLIGI

1. www.niet.uz saytidan Register (Ro’yxatdan o’tish) bandiga kirasiz

2. Keyingi bosqichda shaxsiy ma’lumotlaringizni kiritasiz va Register (Ro’yxatdn

o’tish) tugmasini bosing.
3. ! Login va parolingizni saqlab oling, yuborgan maqolalaringiz holatini shaxsiy
profilingiz orqali kuzatib turishingiz hamda kamchiliklari mavjud bo’lsa shaxsiy
kabinetingiz orqali ko’rishingiz mumkin.

4. Keyingi oynada View submission (Taqdim etilgan maqola holatini kuzatish),

Make a new submission (yangi maqola taqdim etish), Edit my profile (Shaxsiy profilni
tahrirlash) va asosiy oynaga o’tishingiz mumkin.
Maqola taqdim etish uchun Make a new submission (yangi maqola taqdim etish)
bandiga kiring
5. Yuklash oynasi orqali Upload File (Fayl yuklash) tugmasini bosish orqali
maqolani Word formatidagi faylini yuklang

6. Faylni yuklaganingizdan so’ng uni Article text (maqola matni) yoki Others
(boshqa fayl) ekanligini tanlang

7. Undan so’ng Ekspert Xulosasini (pdf formatida) Add files (fayl qo’shish)
tugmasini bosish orqali yuklang va faylni Other bandini tanlab qo’ying

8. Undan so’ng Fan yo’nalishi bo’yicha fan doktori taqrizini (pdf formatida) Add
files (fayl qo’shish) tugmasini bosish orqali yuklang va faylni Other bandini tanlab
qo’ying

9. Undan so’ng antiplagiat.uz sayti orqali olingan plagiat so’rovi natijasini (pdf
formatida) Add files (fayl qo’shish) tugmasini bosish orqali yuklang va faylni
Other bandini tanlab qo’ying.
 ! Antiplagiat natijasi 70 % dan past chiqqan maqolalar jurnalda chop etilmaydi.
10. Barcha fayllar yuklab bo’lingandan so’ng Save and continue (saqlash va davom
etish) tugmasini bosing.

11. Keyingi bosqichda Prefix bandiga maqola UDK raqami va Title bandiga Maqola
mavzusi kiritaldi.

12. Abstract bandida maqolani annotatsiyasi va Add contributors bandida sizda

boshqa muaalif bo’lsa uning ma’lumotlari kiritiladi. Keywords bandida
maqolaning kalit so’zlari kiritiladi (har bir kiritilgan kalit so’zdan keyin
kompyuter enter tugmasini bosib keyin ikkinchisi kiritiladi).

13. Barcha amallar bajarilganidan so’ng Save and continue (Saqlash va davom etish
tugmasi bosiladi.)

14. Keyingi ochilgan oynada siz maqolangizni tahririyatga yuborishingiz uchun Finish
submission (Yuborishni yakunlash) tugmasini bosishingiz yoki ortga qaytib qayta
tahrirlashingiz mumkin bo’ladi. Hammasi talab darajasida bo’lsa Finish
submission tugmasini bosing.